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Summary Herbal medicinal products are indispens-
able in children, e. g., in functional gastrointestinal
diseases and coughs and colds, especially when avail-
able in liquid dosing forms for which dosing can be
adapted ideally to different age groups. Despite be-
ing generally accepted as safe, the ethanol content
of many of these products, necessary for Galenic
reasons, has raised questions regarding their safety.
Therefore, safety data from more than 50,000 children
in noninterventional pediatric studies with these
products, as well as data from routine clinical use
in several million children, were assessed. No evi-
dence of the involvement of the ethanol content in
any adverse drug reactions was found. This allows us
to conclude that these herbal medicinal products are
safe in the age groups for which they are authorized
or registered and that the present labeling is adequate
to allow for their safe use in the pediatric population.
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Ethanol in pflanzlichen Arzneimitteln für Kinder
Daten aus pädiatrischen Studien und der Routine-
Pharmakovigilanz
Zusammenfassung Pflanzliche Arzneimittel gehören
bei Kindern zum unverzichtbaren Arzneimittelschatz,
beispielsweise bei funktionellen gastrointestinalen Er-
krankungen sowie Husten und Erkältung. Dies trifft
insbesondere auf flüssige Darreichungsformen zu, bei
denen die Dosierung ideal an unterschiedliche Alters-
gruppen angepasst werden kann. Obwohl sie generell
als sehr sicher gelten, wirft der Alkoholgehalt vieler
dieser Arzneimittel, der aus galenischen Gründen not-
wendig ist, immer wieder Fragen auf. Daher wurden
Sicherheitsdaten von über 50.000 Kindern aus nicht-
interventionellen Studien (NIS) sowie aus der Routi-
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ne-Pharmakovigilanz bei Arzneimitteln, die an meh-
reren Millionen Kindern angewendeten wurden, aus-
gewertet. Es wurden keine Hinweise auf durch den Al-
koholgehalt bedingte Nebenwirkungen gefunden. Da-
raus lässt sich schließen, dass diese pflanzlichen Arz-
neimittel in allen Altersgruppen, für welche sie zu-
gelassen oder registriert sind, gefahrlos angewendet
werden können, und dass die gegenwärtigen Texte in
Fach- und Gebrauchsinformationen eine unbedenkli-
che Anwendung bei Kindern sicherstellen.
Schlüsselwörter Kinderarzneimittel · Phytotherapie ·
Flüssige Darreichungsform · Fach- und Gebrauchsin-
formation · Nutzen-Risiko-Bewertung
Introduction
Ethanol is a component of many herbal fluid prepara-
tions [1], since it is an excellent solvent for the extrac-
tion of herbal drugs and contributes to the stability
of these medicines. Toxicological and pharmacoki-
netic evaluations have shown that the small amounts
of ethanol applied with therapeutic doses are safe
even in children [2, 3], while for potential surrogate
solvents, e.g., glycerol or propylene glycol, toxicolog-
ical proof of safety is not equally convincing [3, 4].
Typical doses of herbal medicines for children aged
6–12 years contain 0.07–0.18 g ethanol, which is equiv-
alent to, e. g., 31–75 ml of apple juice (with an ethanol
content of 0.3%), and is eliminated from the blood
Table 1 Studieswithherbalmedicinal products in children (in alphabetical order)







n = 312 children (1–4 years) 2.5 ml 6 × daily 4.9 0.097 [14–16] 3
n = 324 children (5–12 years) 5.0 ml 6 × daily 0.194
Bronchicum® Elixir, oral
liquid
n = 111 children (1–4 years) 2.5 ml 6 × daily 4.9 0.097 [16, 17]d 0
n = 109 children (5–12 years) 5.0 ml 6 × daily 0.194
Bronchicum® Tropfen, oral
liquid
n = 110 school children (6–12 years ) 25 drops 5 × daily 27.7c 0.274 0
Bronchicum® Elixir, oral
liquid
n = 474 children (1–4 years) 2.5 ml 6 × daily 4.9 0.097 [18, 19] 3
n = 365 children (5–12 years) 5.0 ml 6 × daily 0.194
Bronchicum® Elixir, oral
liquid
n = 200 infants (6–12 months) 1.0 ml 6 × daily 4.9 0.039 [20, 21]d 1
Contramutan® Tropfen, oral
liquid
n = 85 infants (6–12 months) 2–3 drops 12 × daily 33.4c 0.040 [12] 0
n = 95 children (1–6 years) 3–5 drops 12 × daily 0.066
n = 90 school children (6–12 years) 4–7 drops 12 × daily 0.092
Contramutan® Saft, oral
liquid
n = 174 infants (6–12 months) 1.5–2.0 ml 12 × daily 3.6 0.057 0
n = 195 children (1–6 years) 2.0–3.5 ml 12 × daily 0.100
n = 188 school children (6–12 years) 3.0–5.0 ml 12 × daily 0.142
Contramutan® Saft, oral
liquid
n = 100 infants (6–12 months) 2.0 ml 12 × daily 3.6 0.057 [22]d 0
n = 100 children (1–6 years) 4.0 ml 12 × daily 0.114
n = 100 school children (7–12 years) 5.0 ml 12 × daily 0.142
Iberogast®, oral liquid n = 642 infants (under 3 months) 0.33 ml 3 × daily 31.0c 0.081 [23] 0
n = 7709 infants (3 months–3 years) 0.4 ml 3 × daily 0.098
n = 12,802 (4–6 years) 0.5 ml 3 × daily 0.122
n = 19,808 (7–12 years) 0.75 ml 3 × daily 0.184
within 1–3min. These doses lead to amaximum blood
ethanol content of 0.008–0.015 g/l, calculated under
assumption of the worst case scenario.
Regulations in Germany [5] require a warning la-
bel if an adult single dose contains 0.5 g or more
of ethanol and this also applies to lower doses of
the same product for children. The French view [6]
allows an ethanol content per single dose leading
to a blood ethanol concentration not greater than
0.125 g/l. More recently, a draft for a Q & A paper of
the European Medicines Agency (EMA) [7] was pub-
lished. There, a warning is issued for a single dose
of 6 mg/kg or more (this is equivalent to a dose of
120 mg ethanol or 50 ml apple juice in a 6-year-old
with a body weight of 20 kg), stating that in children
aged 6 years and younger, drowsiness, behavioral
changes, and impaired ability to concentrate and
participate in school activities can occur.
Given the different regulatory approaches, and
against the background of public discussions triggered
by the problem of recreational misuse of alcoholic
beverages by adolescents [8–10], there is a need for
a systematic evaluation of clinical and pharmacovig-
ilance data on herbal medicines containing ethanol
for children.
Materials and methods
In the pharmacovigilance system in Germany, all
reports of adverse drug reactions (ADRs) on herbal
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Iberogast®, oral liquid n = 13 infants (under 3 months) 0.33 ml 3 × daily 31.0c 0.081 [24] 0
n = 286 infants (3 month–3 years) 0.4 ml 3 × daily 0.098
n = 480 children (4–6 years) 0.5 ml 3 × daily 0.122
n = 1571 school children (7–12 years) 0.75 ml 3 × daily 0.184
Iberogast®, oral liquid n = 389 children (3–6 years) 0.5 ml 3 × daily 31.0c 0.122 [25] 4
n = 591 school children (7–14 years) 0.75 ml 3 × daily 0.184
Monpax® Saft, oral liquid n = 118 infants (7–12 months) + infants
(1–3 years)
2.5 ml 3 × daily 3.9 0.077 [26] 0
n = 119 children (4–7 years) 2.5 ml 4 × daily 0.077
n = 113 school children (8–14 years) 5.0 ml 3 × daily 0.154
Monapax® Tropfen, oral
liquid
n = 118 infants (7–12 months) + infants
(1–3years)
8 drops 3 × daily 32.8c 0.104 0
n = 115 children (4–7 years) 10 drops 3 × daily 0.130
n = 115 school children (8–14 years) 10 drops 4 × daily 0.130
Phytohustil® Hustenreizstiller
Sirup, oral liquid
n = 100 children (under 3 years) 2.5–3 ml 4 × daily 1.1 0.026 [27] 0
n = 115 children (3–6 years) 5 ml 4 × daily 0.043
n = 98 school children (6–12 years) 5 ml 5 × daily 0.043
Phytohustil® Hustenreizstiller
Sirup, oral liquid
n = 61 infants (under 3 months) 2.5 ml 4 × daily 1.1 0.022 [28]d 0
n = 128 infants (3 month to 2 years) 3.4 ml 4 × daily 0.030
n = 188 children (3–5 years) 4.3 ml 4 × daily 0.037
n = 222 school children (6–12 years) 4.6 ml 5 × daily 0.040
Phytobronchin® Saft S
Lösung, oral liquid
n = 220 infants (under 1 year) 2.5ml 3 × daily 5.0–8.0 0.158 [29] 4
n = 267 children (1–2 years) 3 m 3 ×daily 0.190
n = 352 children (3–5 years) 5 ml 3 × daily 0.316
n = 401 school children (6–12 years) 5 ml 3–4 × daily 0.316
Soledum® Hustensaft, oral
liquid
n = 18 infants (under 2 years) 1.25 ml 3–4 × daily 5.8 0.057 – 0
n = 105 children (2–6 years) 2.5 ml 3–4 × daily 0.115
n = 19 school children (7–10 years) 5 ml 3–4 × daily 0.229
Sum n = 50,316 children (0–12 years) – – – – 15
aTotal number of adverse drug reactions (ADRs): n = 15; all not severe and known; all unrelated to ethanol
b For medicines applied as drops, a volume of 0.05 ml/drop was assumed
cTaken diluted with water, according to package leaflet
dReferences are congress abstracts or internal reports as part of a PSUR
medicinal products in Germany are collected by the
manufacturers. Line listings and data from periodic
safety update reports (PSURs) on ADRs for herbal
medicinal products up to 2009 containing ethanol
were provided by manufacturers and assessed by the
authors regarding a potential causality between the
reports and the ethanol content of the medicines.
For the same medicines, sales figures for Germany
from IMS Health GmbH, Frankfurt/Main, Germany,
were provided for the years 2005–2009, separately for
total sales and sales prescribed by physicians and
reimbursed by the health insurance. These Rx figures
represent mainly prescriptions to children, as these
medicines are reimbursed in Germany only for chil-
dren up to 12 years of age and for adolescents up
to 18 years of age with developmental disturbances
(according to § 34, paragraph 1, No 1 and 2, Sozialge-
setzbuch V, Germany) but they are not reimbursed in
adults. Total sales figures (according to PSUR data)
provided by the manufactures are given as daily doses
(assuming adult doses for precautionary reasons) and
patient numbers, assuming a treatment duration of
4 weeks.
In addition, all clinical studies in children avail-
able for these medicines were collected and the num-
bers of children and adults included as well as the
ethanol doses corresponding to a single dose were
listed. Studies available from congress abstracts or
company reports are listed in Table 1. Single dose,
daily dose, and ethanol content are according to in-
formation in the AMIS database accessible via DIMDI,
Bonn, Germany. Ethanol content is given per single
dose, as the small amounts of ethanol applied per sin-
gle dose aremetabolized within seconds orminutes so
that dosing according to the therapeutic dosing sched-
ule cannot lead to an accumulation [4]. Numbers of
ADRs were listed and it was evaluated whether they
were attributable to the ethanol content of the medic-
inal products.
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Table 2 Safetydata for someherbalmedicinal productscontaining ethanola
Herbal medicinal product Period Daily doses sold (n,
million)




Allergo-loges® 2003–2009 3.4 0.1 None
Bronchicum® Elixir 2004–2009 19.3 1.6 None
Bronchicum® Tropfen 2004–2009 47.8 4.0 None
Contramutan® N Saft 2004–2009 4.8 0.4 None
Contramutan® Tropfen 2004–2009 2.1 0.2 None
Diarrhoesan® 2003–2009 4.4 0.6 None
Iberogast® 1993–2009 636.9 22.7 None
Influex® 1993–2009 15.5 1.5 None
Melrosum® Hustensirup 2004–2009 2.1 0.2 None
Monapax® Saft 2004–2009 7.2 0.6 None
Monapax® Tropfen 2004–2009 1.5 0.1 None
Phytobronchin® Saft S Lösung 1994–2009 3.4 0.4 None
Phytohustil® Hustenreizstiller Sirup 2000–2009 11.4 1.4 None
Soledum® Hustensaft 2004–2009 3.5 0.3 None
Soledum® Hustentropfen 2004–2009 1.3 0.1 None
Total 764.6 34.3 None
aFigures provided by the manufacturers. Figures are available partly from 1993 and partly from 2003/2004 on up to 2009
Table 3 Salesfiguresof someherbalmedicinal products
containing ethanol






Bronchicum® Elixir 8.23 2.22
Bronchicum® Tropfen 5.81 0.58
Contramutan® Saft 3.16 1.52
Contramutan® Tropfen 0.90 0.18
Melrosum® Sirup 0.74 0.40
Monapax® Saft 2.69 1.51
Monapax® Tropfen 0.31 0.13
Soledum® Hustensaft 1.410 0.48
Soledum® Tropfen 0.17 0.05
Diarrhoesan® 1.04 0.58










Data from clinical studies
For an evaluation of the experience gained from the
therapeutic use of these medicines, 17 prospective
and retrospective studies with ten herbal medicinal
products were analyzed, containing ethanol at doses
of 0.022–0.274 g per single application, depending on
the age group. These studies cover 50,316 children of
0–12 years of age (Table 1). In these studies, altogether
15 ADRs have been described, none of which was at-
tributable to the ethanol content of the medicines.
The inclusion of three studies comprising 1041 chil-
dren solely documented in congress abstracts or inter-
nal reports submitted to regulatory authorities does
not change this picture.
Pharmacovigilance data and patient exposure
Of the medicinal products listed in Table 1 and six ad-
ditional medicinal products containing ethanol, dur-
ing the period from 2005 to 2009 more than 764 mil-
lion daily doses were sold, which corresponds to more
than 33 million patients (Table 2).
From the packages of these medicines sold in Ger-
many between 2005 and 2009, 48.1 million were sold
over the counter, of which 10.8 million prescriptions
were covered by health insurance (Table 3). The lat-
ter can be assumed to have been used in children by
about 90%.
ADRs in these medicines are covered by the phar-
macovigilance system, as mentioned earlier, and no
ADRs attributable to the ethanol content have been
reported.
Discussion
There is a wide use of herbal medicinal products con-
taining small amounts of ethanol, in the range be-
tween 0.022 and 0.274 g per single dose, depending
on the respective medicinal product and the different
age groups. These doses are clearly within the range of
ethanol doses given to children with normal food and
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drinks accepted as safe in this age group, for example,
a typical serving of apple juice (100 ml) is expected
to have 0.240 g ethanol [4]. Liquid dosage forms have
an advantage for use in children, as it is possible to
adapt doses to the respective age groups. Ethanol is
specified as the extraction solvent for herbal medic-
inal products in all relevant pharmacopeias, and re-
placement by other solvents like glycerol or propylene
glycol and by the addition of preservatives is not gen-
erally applicable, as the toxicological proof of safety
for these substances is not equally convincing [4, 11].
Therefore these medicines are rated as safe for use
in children by regulatory agencies and are also per-
ceived as safe by health professionals and consumers
[2]. The data presented here give strong support to
these ratings.
The use of these medicines is very widespread:
During the period 1993/2004–2009, more than 700
million daily doses were sold, which can be assumed
to correspond to more than 30 million patients tak-
ing these medicinal products. Even when assuming
that, for example, 50% of the doses sold are not
used (which is likely to be highly exaggerated in the
case of OTC products paid by the patients themselves
and indicated in frequently occurring diseases such
as coughs and colds and functional gastrointestinal
diseases), these figures are impressive, given that no
ADRs attributable to ethanol have been reported.
According to Table 3, about 20% of the 50 million
packages of these medicinal products sold within this
5-year period can be assumed to have been prescribed
to children. Thus, about three million children (given
very conservative assumptions probably significantly
underestimating the real figures) can be assumed to
be included in the overall patient figures given, un-
derlining the relevance of the conclusions to children.
From studies, i. e., from therapeutic use controlled
by physicians, the use of these products in more than
50,000 children of different age groups is documented.
The studies differed in design (retro- and prospec-
tive noninterventional studies, NIS), which can be as-
sumed to be the cause of the different figures of ADRs
per patient, with prospective studies usually generat-
ing higher figures; however, it can also be assumed
that no serious or otherwise significant side effects
would have been missed by the physicians involved.
In this survey, all available evidence is included, also
taking into account congress abstracts and internal re-
ports submitted to regulatory authorities, as they add
to the overall picture and are in line with the other
studies, apparently without introducing a bias. The
number of ADRs is overall low, and their analysis re-
sulted in the conclusion that they do not involve any
effects potentially related to the ethanol content of the
medicinal products.
The data presented here are in accordance with the
conclusions drawn from data on the ADME of ethanol
and the commonly accepted ethanol uptake in chil-
dren with their usual nutrition [4], which is far below
doses that could lead to pharmacological or toxicolog-
ical effects. This also applies to the case of a study in
which single doses corresponding to 142 mg ethanol
were applied to children between 6 and 12 years up to
12 times per day [12], as this single dose of ethanol is
eliminated within 3 min [4] so that an accumulation
is not to be expected. That relevant blood ethanol lev-
els are not achieved has recently also been confirmed
by a pharmacokinetic study with one of the medic-
inal products included in this review, Bronchicum®
Elixir [11], where children of 1–12 years of age were
included. Therefore, there is no specific risk to be as-
signed to the ethanol content of these medicines. The
ethanol content consequently does not have a rele-
vant impact on the benefit–risk assessment of these
medicines in children. This applies likewise to prod-
ucts with a marketing authorization based on a clini-
cal proof of efficacy and to products registered accord-
ing to EU regulations [13] based on their traditional
use, as these products may also not be harmful in the
specified conditions of use and their efficacy needs
to be plausible on the basis of long-standing use and
experience.
Therefore, the texts in the summary of the prod-
uct characteristics of these products, such as those in
accordance with the present regulations in Germany,
which in most products only state the percentage of
ethanol content in the solution [5], are appropriate,
and any further texts or warnings would suggest a risk
that is not relevant and could therefore be misleading.
Conclusion
The data on pharmacokinetics, pharmacodynamics,
and toxicology confirm the long-standing experience
with herbal medicinal products, according to which
the ethanol content of these products, such as those
presently authorized or registered in EU countries,
does not give cause for concern regarding their safety
in children. The data do not support adding warning
labels that apply to doses in the range of or even be-
low those found in usual nutrition that is accepted as
safe in children. The regulation already in force to-
day for these products is therefore fully in accordance
with the present scientific and medicinal state of the
art.
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